Company Performance Metrics
Ronald Herberman: Senior V.P. of R&D & Chief Medical Officer- Christopher Pearce: Director & Chief Financial Officer
At Immune Therapeutics (formerly known as TNI BioTech, Inc.), their goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Their products, technologies, and patents are designed to harness the power of the immune system
to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapy.
Immune Therapeutics' most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low-dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to the activation and expansion of various cells in the immune system.
